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Malaria is a tropical infectious disease that affects over 219 million people worldwide.
Due to the constant emergence of parasitic resistance to the current antimalarial
drugs, the discovery of new antimalarial drugs is a global health priority. Multi-target
drug discovery is a promising and innovative strategy for drug discovery and it is
currently regarded as one of the best strategies to face drug resistance. Aiming to
identify new multi-target antimalarial drug candidates, we developed an integrative
computational approach to select multi-kinase inhibitors for Plasmodium falciparum
calcium-dependent protein kinases 1 and 4 (CDPK1 and CDPK4) and protein kinase
6 (PK6). For this purpose, we developed and validated shape-based and machine
learning models to prioritize compounds for experimental evaluation. Then, we applied
the best models for virtual screening of a large commercial database of drug-like
molecules. Ten computational hits were experimentally evaluated against asexual blood
stages of both sensitive and multi-drug resistant P. falciparum strains. Among them,
LabMol-171, LabMol-172, and LabMol-181 showed potent antiplasmodial activity at
nanomolar concentrations (EC50 ≤ 700 nM) and selectivity indices >15 folds. In addition,
LabMol-171 and LabMol-181 showed good in vitro inhibition of P. berghei ookinete
formation and therefore represent promising transmission-blocking scaffolds. Finally,
docking studies with protein kinases CDPK1, CDPK4, and PK6 showed structural
insights for further hit-to-lead optimization studies.
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INTRODUCTION
Malaria is a serious infectious disease that affects 219 million people worldwide and kills
over 435,000 patients annually, especially pregnant women and children in Sub-Saharan Africa
(WHO, 2018). The disease is transmitted to humans through the bites of infected female
Anopheles mosquitoes and caused by Plasmodium genus parasites (Ashley et al., 2018). Among
them, P. falciparum is the most devastating species responsible for severe form of malaria and
deaths (WHO, 2017).
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Current control and eradication demands a combination
of drugs with different mechanisms of action. Despite of
compelling investment for controlling and eliminating this
infectious disease, resistant parasite strains have been reported
to all major antimalarial drugs (Wu et al., 1996; Triglia
et al., 1998; Srivastava et al., 1999; Wellems and Plowe, 2001),
including front-line artemisinin-based combination therapies
(Rogers et al., 2009; Witkowski et al., 2013; Ashley et al., 2014).
All these aspects highlight the urgent need for the discovery
of new antimalarial drugs by identifying molecules with novel
mechanisms of action and efficient against resistant parasite
strains (Burrows et al., 2017).
The complete genome sequencing of P. falciparum (Gardner
et al., 2002) has provided new and valuable information on its
biological pathways, identifying potentially relevant biological
targets for therapeutic intervention. In this context, protein
kinases have been investigated because of their importance in
several essential signaling pathways, e.g., homeostasis, apoptosis
and cell division (Lucet et al., 2012; Bullard et al., 2013).
Kinases catalyze the transfer of phosphate groups from ATP
to specific substrates. These enzymes share a high degree of
sequence and structural homology between the ATP binding
sites, making them potential targets to be grouped and inhibited
simultaneously by a single molecule. This mechanism, known
as multi-kinase inhibition (MKI), provides a synergistic effect
responsible for increasing the effectiveness of the kinase
inhibitors, and consequently preventing the emergence of
parasite resistance (Garuti et al., 2015). On the other hand,
promiscuity is the main challenge in parasitic MKI design, which
requires selective inhibitors unable to interact with host protein
(Davies et al., 2000; Bain et al., 2003, 2007). However, the
vast phylogenetic distance between Apicomplexans and humans
(Ward et al., 2004) makes possible the development of multi-
target and selective antimalarial candidates.
Calcium-Dependent Protein Kinases (CDPKs), a kinase
family of plants and some alveolates, absent in metazoans, have
been considered as one of the main effectors of calcium signaling,
demonstrating a pronounced importance in apicomplexans,
controlling a range of events in the parasite life cycle (Nagamune
et al., 2008). PfCDPK1 is expressed in all Plasmodium life
stages (Sebastian et al., 2012), being essential for the sexual
stage of the parasite (Jebiwott et al., 2013; Bansal et al., 2018).
Meanwhile, PfCDPK4 regulates cell cycle progression in the
male gametocyte (Billker et al., 2004) and, together with Protein
Kinase G, is activated during hepatocytes invasion by sporozoite
(Govindasamy et al., 2016). Protein Kinase 6 of P. falciparum
(PfPK6), classified as Cyclin-Dependent Kinase (Chakrabarti
et al., 1993), appears to be located in the cytoplasm and nucleus,
mainly expressed in trophozoite, schizonts and segmenters stages
(Bracchi-Ricard et al., 2000). The low identity between PfPK6
Abbreviations:MKI, multi-kinase inhibitors; CDPK1, calcium-dependent protein
kinases 1; CDPK4, calcium-dependent protein kinases 4; PK6, protein kinase 6;
ML, machine learning; ROC, receiver operating characteristic curve; AUC, area
under the ROC curve, BEDROC, Boltzmann-enhanced discrimination of ROC;
EF, enrichment factor; SE, sensitivity; SP, specificity; VS, virtual screening; CCR,
correct classification rate; PPV, positive predictive value; NPV, negative predictive
value; and SI, selectivity index.
and human Cyclin-Dependent Kinase 2 brings out PK6 as a
potential antimalarial target. Its numerous variations in the active
site amino acids can be exploited to design selective plasmodial
inhibitors (Waters and Geyer, 2003). Therefore, the structural
dissimilarities between human kinases and Plasmodium-specific
kinases, such as CDPK1 and CDPK4 and PK6, turn these
enzymes attractive targets for development of new multi-target
antimalarial therapies (Lucet et al., 2012; Crowther et al.,
2016). Recently, Crowther and colleagues (Crowther et al.,
2016) reported an experimental screening of ∼14,000 cell-
active compounds against PfCDPK1 and PfCDPK4, mitogen-
associated protein kinase 2, PK6, and protein kinase 7. They
found potent inhibitors (IC50 <1µM) for multiple kinases
simultaneously, with low cytotoxicity to human, bypassing the
challenging of MKI promiscuity. Thus, the availability of the
whole dataset of compounds with data for kinase inhibition
allowed us to generate and validate robust and predictive shape-
based models, that were integrated with machine learning (ML)
models for a virtual screening workflow aiming to prioritize
compounds to be experimentally evaluated in vitro against
asexual blood stages of both sensitive and multi-drug resistant
P. falciparum, and against sexual stages of P. berghei, as well as in
mammalian cells. This integrative analysis allowed us to identify
new potential and selective antiplasmodial hits.
MATERIALS AND METHODS
The overall study design is shown in Figure 1. Briefly, we
followed the successive steps: (I) dataset collection, curation, and
integration of compounds with activity against CDPK1, CDPK4,
PK6, and asexual-blood stages of P. falciparum; (II) development
of shape-based models for CDPK1, CDPK4, and PK6, and
machine learning models for P. falciparum; (III) virtual screening
of ChemBridge database (∼1 million compounds); and (IV)
experimental validation of prioritized compounds against asexual
blood stage of P. falciparum (sensitive and multi-drug resistant
strains), sexual blood stages of P. berghei and cytotoxicity in
mammalian cells.
Computational
The whole project was built envisioning best practices of ML
modeling (Tropsha, 2010; Cherkasov et al., 2014).
Data Integration and Curation
In this study, five datasets extracted from the PubChem Bioassay
database (Wang et al., 2012) were explored to build shape-based
models and ML models. All datasets were carefully standardized
according to the protocol described by Fourches et al. (2010,
2015, 2016). Thus, explicit hydrogens were added; counter
ions, inorganic salts, polymers, mixtures, and organometallic
compounds were removed; and specific chemotypes (aromatic,
nitro groups and others) were normalized using ChemAxon
Standardizer (v. 6.1, ChemAxon, Budapest, Hungary, www.
chemaxon.com). Then, a go/no-go criteria of 1µM for the
progression of P. falciparum kinase inhibitors and antiplasmodial
hits (Katsuno et al., 2015) was used as activity threshold to
distinguish active vs. inactive compounds. Furthermore, we
Frontiers in Chemistry | www.frontiersin.org 2 November 2019 | Volume 7 | Article 773
Lima et al. Multi-Kinase Approach for Antiplasmodial Hits
FIGURE 1 | Overall pipeline designed for the identification of new antiplasmodial compounds.
performed the analysis and exclusion of duplicates as follows: (a)
if the reported outcomes of the duplicates were the same, one
entry was retained in the dataset and the other excluded, and
(b) if duplicates presented discordance in biological activity, both
entries were excluded from dataset. A brief description of the
datasets is presented below.
• CDPK1: 181 active compounds with IC50 ≤1µM and 13,270
inactive compounds with IC50 >1µM (National Center for
Biotechnology Information, 2016a);
• CDPK4: 55 active compounds with IC50 ≤1µM and 13,396
inactive compounds with IC50 >1µM (National Center for
Biotechnology Information, 2016b);
• PK6: 65 active compounds with IC50 ≤1µM and 13,386
inactive compounds with IC50 >1µM (National Center for
Biotechnology Information, 2016c);
• P. falciparum 3D7 (drug-susceptible) strain: 3,497 active
compounds with EC50 ≤1µM and 4,376 inactive compounds
with EC50 >1µM (National Center for Biotechnology
Information, 2009a, 2010a, 2011a, 2013);
• P. falciparum W2 (drug-resistant) strain: 3,637 active
compounds with EC50 ≤1µM and 3,766 inactive compounds
with EC50 >1µM (National Center for Biotechnology
Information, 2009b, 2010b, 2011b, 2012).
The inhibitory activity against each kinase was considered
proportional to ATP consumed, as determined from
measurements of residual [ATP] with the luciferase-based
assay. So, all active compounds used to build shape-based models
are inhibitors of ATP binding site (Crowther et al., 2016). All
datasets generated for this study are included in the manuscript
and the Supplementary Files.
Shape-Based Models
The shape-based models were built to distinguish active vs.
inactive compounds for P. falciparum CDPK1, CDPK4, and
PK6. Initially, the curated datasets were balanced by linear
under-sampling method obeying a proportion of 1:36, aiming
to reproduce the chemical space of an HTS, which contain
more non-inhibitors. Then, 200 conformations were generated
for each compound using OMEGA v.2.5.1.4 software (OMEGA
2.5.1.4: OpenEye Scientific Software, Santa Fe, NM. http://www.
eyesopen.com) (Hawkins et al., 2010), while the protonation
states at neutral pH and AM1-BCC charges (Jakalian et al.,
2002) were estimated using QUACPAC v.1.7.0.2 (QUACPAC
1.7.0.2: OpenEye Scientific Software, Santa Fe, NM. http://
www.eyesopen.com). To create the shape-based models, the
most potent compounds against each kinase (see details in
Table S1) were loaded into ROCS software v.3.2.2.2 (ROCS
3.2.2.2: OpenEye Scientific Software, Santa Fe, NM. http://
www.eyesopen.com) (Hawkins et al., 2007) and used as query
compound. Then, the output conformations of active and
inactive compounds were aligned by a solid-body optimization
process that maximizes the overlap volume with queries, and
ranked according to Reference Tversky Combo scoring function
(Hawkins et al., 2007). Finally, the predictive performance of the
shape-based models was assessed using the following metrics:
Receiver Operating Characteristic (ROC) curve, Area Under
the ROC Curve (AUC), Boltzmann-Enhanced Discrimination of
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ROC (BEDROC) and Enrichment Factor (EF). These statistic
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Here, SE denotes sensitivity and SP specificity, RIE robust initial
enhancement, Ra ratio of actives in the list.
The ROC curve provides a graphical representation of a
predictor’s behavior by plotting the true (Braga and Andrade,
2013; Neves et al., 2016) positive rate [sensitivity (SE)]
against the 1 minus false positive rate [1—Specificity (SP)].
See SE e SP equations in ML section. The ideal predictive
model would yield a point in the upper left corner of
the ROC plot, representing 100% SE and SP. The AUC is
the probability that a model will rank an active compound
higher than a randomly chosen inactive. The EF shows
how many times the shape-based models retrieved active
compounds when compared with random selection (Braga and
Andrade, 2013). Lastly, BEDROC uses an exponential decay
function to favor models that pile up active compounds near
the top of the rank-ordered list from the virtual screening
(Huang and Wong, 2016).
Machine Learning Models
Binary ML models were built to distinguish active vs.
inactive compounds for P. falciparum. The curated datasets
for P. falciparum 3D7 and W2 strains were balanced in a
proportion of 1 active:1 inactive. For this, the original chemical
space of each library was maintained through linear under-
sampling method based on k-nearest neighbors distances of
each inactive to all active. ML models were built using an
in-house workflow, implemented in KNIME (Berthold et al.,
2009) including many modules as multiple machine learning
methods, performance metrics, applicability domain, and Y-
randomization test. Five molecular fingerprints implemented in
RDKit (v.2.4.0) (http://www.rdkit.org) were used: (i) Morgan
and (ii) FeatMorgan fingerprints, generated using radius of
2 and bit vector of 1,024 bits (Morgan, 1965; Rogers and
Hahn, 2010); (iii) Molecular ACCess System (MACCS) structural
keys (Dill et al., 1981; Anderson, 1984; Durant et al., 2002);
(iv) AtomPair fingerprint with bit vector of 1,024 bits and
path length ranging between 1 and 10 (Carhart et al., 1985);
and (v) Avalon fingerprint with bit vector of 1,024 bits
(Gedeck et al., 2006). The Random Forest method was the
chosen algorithm to generate the models and to produce the
final prediction based on combination of each decision tree
(Breiman, 2001; Svetnik et al., 2003).
Moreover, for ML models’ robustness estimation, 5-fold
external cross-validation was performed. In this method, each
dataset is randomly and equally divided into five subsets. Then,
one of them is outwardly maintained as external set and the
remaining four establish the modeling set. This procedure is
repeated five times, allowing each subset to be used once as
external validation set. The performance and robustness of ML
models were assessed through statistic metrics such as: sensitivity
(SE), specificity (SP), Correct Classification Rate (CCR), Positive
Predictive Value (PPV), and Negative Predictive Value (NPV).





















Here, TP and TN correspond respectively to the number of true
positives and true negatives. FP and FN represent, respectively,
the number of false positives and false negatives.
In addition, 10 rounds of Y-randomization were conducted to
evaluate whether the correlation between structure and activity
occurred by chance. To measure the reliability of developed ML
models, the Applicability Domain (AD) was estimated using
Euclidean distances between each external compound, obtained
by 5-fold cross-validation procedure, and their respective nearest
neighbor in modeling set. These distances were related to the
pre-defined AD threshold level. Toward a pre-defined distance
threshold, the distance superior to this threshold were considered
unreliable (Zhang et al., 2006).
In this study, we defined AD as:
DT = y+ Zσ (9)
Here, DT is a distance threshold, y is the average Euclidean
distance of the k nearest neighbors of each compound of the
training set, σ represents the standard deviation of the Euclidean
distances and Z is an arbitrary parameter to control the level of
significance. We set the default value of 0.5 for Z.
Consensus modeling was done combining the best MLmodels
of each fingerprint type with Random Forest machine learning
method. This approach was adopted with the aim to capture
the different chemical information provided by each fingerprint,
enriching the prediction during virtual screening and minimize
individual model’s error. Each individual model was applied to
predict the activity of selected compounds after passing through
shape-based screening filter. For this purpose, five models for
3D7 strain and five models for W2 strain were employed in
separate runs. This way, when a model predicted a compound as
active, a value of 0.2 was given, thus the final value of probability
to be active was ranging from 0 to 1. Only compounds inside AD
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and predicted as active at least in three models (probability≥ 0.6)
of both strains were picked up.
Virtual Screening
Developed shape-based andMLmodels were used for VS of∼1.1
million compounds available on ChemBridge database (http://
www.chembridge.com/) aiming to identify new potential kinases
inhibitors with antiplasmodial activity. Prior to screening,
the database was filtered using Veber (Veber et al., 2002)
and Lipinski’s rules (Lipinski et al., 2001) to prioritize drug-
like molecules, using FILTER (OMEGA 2.5.1.4: OpenEye
Scientific Software, Santa Fe, NM. http://www.eyesopen.com).
Subsequently, molecules were filtered by shape-based models
developed for CDPK1, CDPK4, and PK6. Then, the common
compounds between the top 10% of each kinase list had
their antiplasmodial activity predicted by consensus ML models
developed for 3D7 and W2 strains. The compounds prediction
were recognized if it were found within the AD of more than
50% of all models used in consensus prediction. Finally, the
selected virtual hits were purchased and submitted to in vitro
experimental evaluation.
Homology Modeling
The amino acid sequence of P. falciparum CDPK1 and PK6 were
not available on the Protein Data Bank at the time this work
was conducted. Consequently, homology models were built by
comparing the P. falciparum primary sequences with sequences
of homolog proteins (templates) whose 3D structures were
publicly available. Initially, the sequences of P. falciparum kinases
were extracted from the UniProt database (Apweiler, 2004) and
used as target for homology modeling in the SWISS-MODEL
webserver (Bordoli et al., 2009; Biasini et al., 2014). Then,
the tailored models were structurally optimized in GalaxyWEB
server (Ko et al., 2012). Finally, overall stereochemical and
geometrical quality of refined models were investigated using
MolProbity server (Chen et al., 2010).
Docking
Chemical structures of antiplasmodial hits were imported to
Maestro v. 10.7.015 (Schrödinger, LLC, New York, NY, 2016)
and prepared using LigPrep (Schrödinger, LLC). In parallel, the
3D structures of P. falciparum CDPK1, CDPK4, and PK6 were
prepared using the Protein Preparation Wizard available on
Maestro workspace (Schrödinger LLC) as follows: bond orders
and formal charges were adjusted; hydrogen atoms were added
to the proteins; and protonation state of polar amino acids
were predicted by PROPKA (Schrödinger, LLC) (Søndergaard
et al., 2011) at neutral pHs. Before docking studies, grids were
established to each protein ruled by a box space of 10 × 10 ×
10 Å3, and fixing the box on the geometrical center of ATP-
binding site using the receptor grid generation panel of the Glide
(Schrödinger, LLC) (Friesner et al., 2004). Finally, molecular
docking calculations were carried out using Glide Extra Precision
(XP) mode and constraints into hinge region. The docking poses
of each virtual hit were submitted to Prime (Schrödinger, LLC)
for rescoring using the Molecular Mechanics/Generalized Born
Surface Area (MMGBSA) approach with default conditions.
Experimental
Plasmodium Culture
Parasite cultures (3D7 and Dd2 strains) were maintained in O+
human erythrocytes in RPMI 1640 medium supplemented with
0.05 mg/mL gentamycin, 38.4mM HEPES, 0.2% sodium
bicarbonate, and 10% O+ human serum as described
before (Trager and Jensen, 1976). To achieve a synchronic
culture in the ring stage, two consecutive treatments at
48 h intervals with a 5% solution of D-sorbitol were done
(Lambros and Vanderberg, 1979).
Determination of Plasmodium Growth Inhibition by
SYBR Green I
Synchronized ring-stage (> 90%) infected erythrocytes were
dispensed in duplicate into 96-well plates (0.5% parasitemia, 1%
hematocrit) and incubated in dose response format with test
compounds for 72 h. Chloroquine was used as an antimalarial
control and uninfected erythrocytes as negative control. Then,
in vitro susceptibility of parasite to tested drug was measured
by SYBR Green (Hartwig et al., 2013). Following incubation,
the plates were frozen and thawed, and 100 µL of the culture
were transferred to a new black 96-well plate containing 100
µL of lysis buffer (20mM Tris, 5mM EDTA, 0.008% wt/vol
saponin, 0.08% vol/vol Triton X-100, and 0.4 µL/mL of SYBR
Green). After 1 h, the fluorescence was measured at 490 nm
excitation and 540 nm emission (CLARIOstar, Labtech BMG).
The results were compared with control cultures with no drugs.
The EC50 was calculated by plotting the Log doses vs. Inhibition
(expressed as a percentage relative to the control) in Prism 6
(GraphPad Software Inc.). Each test was performed at least three
independent experiments.
Cytotoxicity Assay
The cytotoxicity was evaluated using two different lineages of
mammalian cells: fibroblast-like cell lines derived from monkey
kidney tissue (COS7 cells) and human hepatoma cell line
(HEPG2). The cells were grown in 75 cm2 flasks containing
DMEM medium supplemented with 10% fetal bovine serum
and 0.05 mg/mL gentamicin under a 5% CO2 atmosphere at
37◦C. After harvest of cells, 100 µL aliquots were distributed
in 96-well plates (1 x 104 cells per well) and incubated until
adhesion (∼12 h). The compounds at various concentrations
(100−0.048µM) were placed in the wells in duplicate and
incubated for 72 h. The cell viability analysis were done
by the MMT reduction method (3-[4,5-dimethyl-thiazol-2-yl]-
2,5-diphenyltetrazolium chloride), after the incubation period
(Mosmann, 1983). The optical density was determined at
570 nm (CLARIOstar, Labtech BMG) and the 50% cytotoxicity
concentrations (CC50) were expressed as the percent viability
relative to the control (untreated cells). The selectivity index of
the compounds was determined through the ratio of the CC50 of
both cytotoxicity results (COS7 and HEPG2 cells) and EC50 3D7,
separately. Experiments were performed at least three times.
Inhibition of P. berghei Sexual Stage Progression
Balb/c mice were infected intraperitoneally with the P. berghei
Ookluc line (Calit et al., 2018). Four to five days after infection,
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TABLE 1 | Validation of shape-based models using different queries.
Kinase Model AUC TOP 1% TOP 5% TOP 10%
EF BEDROC EF BEDROC EF BEDROC
CDPK1 I* 0.81 22.10 0.63 10.06 0.50 5.41 0.52
II 0.83 20.99 0.58 7.40 0.41 4.74 0.45
III 0.69 0.55 0.02 2.20 0.09 2.21 0.16
CDPK4 IV* 0.77 3.64 0.13 3.64 0.17 3.27 0.24
V 0.72 3.64 0.13 3.15 0.15 3.27 0.23
VI 0.74 3.64 0.13 3.39 0.15 3.27 0.23
PK6 VII* 0.95 26.15 0.77 13.64 0.68 8.46 0.74
VIII 0.94 26.15 0.75 13.54 0.66 8.62 0.72
IX 0.93 24.62 0.65 13.54 0.64 8.31 0.72
AUC, area under the ROC curve; EF, Enrichmenent Factor; BEDROC, Boltzmann-Enhanced Discrimination of ROC. *Selected model.
the infected blood was collected by cardiac puncture and 4
µL were seeded to a volume of 80 µL of ookinete medium
(Blagborough et al., 2013), at 21◦C, containing 10µM of
compounds or DMSO vehicle control. After 24h incubation
at 21◦C, the nLuc substrate (Nano-Glo, Promega) was added
to each well 1:1 (v:v) and incubated for 5min at 37◦C. The
luciferase activity was measured using a plate luminometer
SpectraMax i3; Molecular Devices and the % of conversion
inhibition were calculated relative to the luciferase activity in
the control assays. This assay was approved by the Ethics
Committee (protocol number 132/2014-CEUA) of the Institute
of Biomedical Sciences—University of São Paulo.
RESULTS AND DISCUSSION
Shape-Based Models
Shape-based models were built to distinguish active vs. inactive
compounds for P. falciparum CDPK1, CDPK4, and PK6.
Initially, the chemical structures of most potent inhibitors of
each protein kinase were used as queries to develop shape-
based models (Table S1). Molecular conformations of queries
were selected according to energy minimization. Subsequently,
the ability of the models to differentiate between the active
and inactive compounds was inspected. Details of model
performance are shown in Table 1. As observed, all models led
to AUC values ranging between 0.69 and 0.95.
Model I showed the best statistical performance for CDPK1,
with EF values of 22.10, 10.06, and 5.41; and BEDROC values
of 0.63, 0.50, and 0.52 at the top 1, 5, and 10% of the ranked
database, respectively. The model IV showed the best statistical
performance for CDPK4, with EF values of 3.64, 3.64, and 3.27;
and BEDROC values of 0.13, 0.17, and 0.24 at the top 1, 5,
and 10% of the ranked database, respectively. Finally, the model
VII showed the best statistical performance for PK6, with EF
values of 26.15, 13.64, and 8.46; and BEDROC values of 0.77,
0.68, and 0.74 at the top 1, 5, and 10% of the ranked database,
respectively. These results indicated that our shape-based models
were statistically robust and therefore would be considered for a
subsequent virtual screening study.
TABLE 2 | Summarized statistical characteristics of ML models accessed by
5-fold cross validation.
Model CCR SE SP PPV NPV Coverage
P. falciparum 3D7 strain
Avalon 0.75 0.72 0.78 0.76 0.73 0.99
MACCS 0.74 0.73 0.75 0.74 0.73 1.00
Morgan 0.75 0.69 0.80 0.78 0.72 0.99
FeatMorgan 0.75 0.71 0.79 0.77 0.73 0.99
AtomPair 0.73 0.70 0.77 0.75 0.72 0.99
Consensus 0.76 0.71 0.80 0.78 0.73 1.00
Consensus rigor 0.76 0.72 0.80 0.78 0.74 0.98
P. falciparum W2 strain
Avalon 0.71 0.67 0.75 0.73 0.70 0.99
MACCS 0.70 0.70 0.70 0.70 0.70 1.00
Morgan 0.71 0.66 0.76 0.73 0.69 0.99
FeatMorgan 0.71 0.68 0.74 0.72 0.70 0.99
AtomPair 0.70 0.69 0.71 0.70 0.69 0.99
Consensus 0.72 0.68 0.76 0.74 0.70 1.00
Consensus rigor 0.72 0.68 0.76 0.74 0.70 0.98
CCR, Correct Classification Rate; SE, Sensitivity; SP, Specificity; PPV, Positive Predictive
Value; NPV, Negative Predictive Value.
ML Models
ML models were built to distinguish active vs. inactive
compounds for P. falciparum sensitive (3D7) and resistant
strains (W2). According to the statistical results of the 5-
fold external cross-validation procedure, the combination of
Avalon, MACCS, Morgan, FeatMorgan, AtomPair fingerprints
with Random Forest algorithm led to predictive MLmodels, with
CCR values ranging between 0.70 and 0.76. Table 2 shows the
detailed performances of the binary ML models.
The model built using Avalon (CCR = 0.75, SE = 0.72, SP
= 0.78, PPV = 0.76, and NPV = 0.73) and Morgan (CCR =
0.75, SE = 0.69, SP = 0.80, PPV = 0.78, and NPV = 0.72)
demonstrated the best performances among all other models
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FIGURE 2 | General workflow of the virtual screening campaign.
developed for P. falciparum 3D7 strain. On the other hand, the
best model developed for prediction activity against W2 strain
was built using Avalon (CCR = 0.71, SE = 0.67, SP = 0.75, PPV
= 0.73, NPV = 0.70), Morgan (CCR = 0.71, SE = 0.66, SP =
0.76, PPV = 0.73, NPV = 0.69), and FeatMorgan (CCR = 0.71,
SE = 0.68, SP = 0.74, PPV = 0.72, NPV = 0.70). Subsequently,
10 rounds of Y-randomization were performed for each data set
(Table S2). The results from this analysis (CCR, SE, SP values
around 0.50) indicate that predictivity of our models was not due
to chance correlation.
Virtual Screening
The virtual screening (VS) was carried out following the
workflow presented in Figure 2. Initially, 1,091,088 compounds
available on ChemBridge database were downloaded. Then,
747,566 molecules with probable oral bioavailability were
prioritized using a drug-likeness filter. Then, conformers and
AM1-BCC charges were generated for each molecule. The
best shape-based models were used to prioritize potential P.
falciparum multi-kinase inhibitors. Subsequently, the 14,878
common structures in top 10% scored list by shape-based filters
were submitted to developed ML models for prediction of
antiplasmodial activity against sensitive and resistant strains. In
addition, the AD was determined in order to set “reliable” and
“unreliable” predictions (Netzeva et al., 2005; Gadaleta et al.,
2016). The predictions were considered reliable when the virtual
hits are within the chemical space of compounds used to trainML
models. At the end of this process, ten putative hits were selected
for biological evaluation.
Experimental
The ten virtual hits were evaluated in vitro against asexual
blood stages of P. falciparum sensitive (3D7), and multi-drug-
resistant (Dd2) strains. The EC50 for each compound (Table 3)
indicate that three compounds (LabMol-171, LabMol-172 and
LabMol-181) were potent at inhibiting the parasite growth
showing activities in nanomolar range against both 3D7 and
Dd2 strains. These results corroborate with go/no-go criteria
established for the progression of P. falciparum kinase inhibitors
and antiplasmodial hits in VS, since the three compounds showed
EC50 < 1µM. The compound LabMol-181 (EC50 = 0.39 and
0.40µM for 3D7 and Dd2, respectively) showed the most potent
activity, when compared with reference drugs, chloroquine (EC50
= 0.02 and 0.15µM for 3D7 and Dd2, respectively). Moreover,
the three most active compounds (LabMol-171, LabMol-172
and LabMol-181) also have a common scaffold (quinazoline),
varying groups at the R1 and R2 positions (Figure 3). In contrast,
LabMol-175 (EC50 3D7 > 5µM) and LabMol-176 (EC50 3D7
= 1.15µM), which also display quinazoline scaffold, shown
reduced inhibition activity against chloroquine-sensitive strain.
This fact can be explainedmainly by the presence of hydrophobic
substituents in position R2 for both compounds, and an electron
withdrawing group (Cl) attached to ring B in LabMol-175.
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TABLE 3 | In vitro evaluation of selected virtual hits against asexual blood stage of P. falciparum 3D7 e Dd2 strains, cytotoxicity on mammalian cells (COS7, HEPG2),









SI* SI** % ookinete
conversion
inhibition (10 µM)
8.77 ± 2.20 3.40 ± 1.68 44.60 ± 3.73 19.95 ± 2.26 5.09 2.27 8.58 ± 7.62
LabMol-169
1.14 ± 0.20 2.02 ± 0.36 7.59 ± 4.09 5.43 ± 2.39 6.66 4.76 11.24 ± 19.47
LabMol-170
0.35 ± 0.08 0.70 ± 0.41 48.39 ± 14.04 19.31 ± 3.69 138.26 55.17 70.02 ± 22.16
LabMol-171
0.43 ± 0.08 0.48 ± 0.17 12.11 ± 1.44 10.21 ± 5.53 28.16 23.74 8.59 ± 13.01
LabMol-172
>5 – – – – – 0.00 ± 0.00
LabMol-173
>5 – – – – – 21.41 ± 36.67
LabMol-174
>5 – – – – – 12.87 ± 22.29
LabMol-175
1.15 ± 0.26 1.71 ± 0.40 34.88 ± 4.06 5.63 ± 1.51 30.33 4.90 20.51 ± 19.45
LabMol-176
>5 – – – – – 8.76 ± 15.18
LabMol-177
(Continued)
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SI* SI** % ookinete
conversion
inhibition (10 µM)
0.39 ± 0.06 0.40 ± 0.10 18.29 ± 1.92 6.13 ± 2.05 46.90 15.72 51.81 ± 23.16
LabMol-181
Chloroquine 0.02 ± 0.01 0.15 ± 0.04 – – – – –
EC50 3D7, half maximal effective concentration in 3D7 strain; EC50 Dd2, half maximal effective concentration in Dd2 strain; CC50 COS7, half maximal cytotoxic concentration on COS7
cell; CC50 HEPG2, half maximal cytotoxic concentration on HEPG2 cell; SI*, selectivity index calculated between CC50 COS7 and EC50 3D7 strain; SI**, selectivity index calculated
between CC50 HEPG2 and EC50 3D7 strain. The data are expressed as mean ± SD of three independent assays.
FIGURE 3 | Common quinazoline scaffold between the discovered hits. The dashed green, blue and red lines indicate the substituents in R1, R2, and R3
positions, respectively.
The selected compounds were also evaluated for their
cytotoxicity against fibroblast-like cell lines derived from
monkey kidney (COS-7 cells) and human hepatocytes
(HEPG2 cells). With respect to selectivity, LabMol-171
and LabMol-172 showed the most promising results, since
they showed selectivity index (SI) ranging between 23.74
and 138.26 (Table 3). It is worth noting that no compound
showed cross-resistance with multi-drug resistant strain (Dd2
EC50/3D7 EC50 ≤ 2 for all compounds), thus suggesting
a different mechanism of action from clinically established
antimalarial drugs.
Previous reports have demonstrated that CDPK1 e CDPK4
have critical rule for parasite gametogenesis, displaying a
potential target for development of transmission-blocking
drugs (Billker et al., 2004; Bansal et al., 2018). Since CDPK1
and CDPK4 compose the present multi-target approach,
we decided to evaluate the potential of these compounds
in inhibiting the formation of ookinetes in vitro, using a
recently described in vitro luciferase assay (Calit et al., 2018).
LabMol-171 and LabMol-181, promising selected compounds
in terms of selectivity and inhibition growing of asexual
blood stages, also showed considerable inhibition at 10µM
(70.02 and 51.81%, respectively) during ookinete formation
in comparison to control. These results demonstrate that
these compounds are active against multiple parasite stages,
comprising human treatment and transmission blocking
to mosquitoes.
Rationalizing Anti-plasmodial Activity
Understanding the interaction pattern between the ligand and
the protein target is essential for designing more potent and
selective analogs. Here, molecular docking studies allowed us to
rationalize the interaction the most potent hit with its associated
protein targets.
As a crystal structure for docking execution was available
only for PfCDPK4 (PDB ID: 4QOX), the 3D structures of
PfCDPK1 and PfPK6 were obtained by homology modeling
process. The modeled and refined proteins were validated using
MolProbity webserver (Table S3). This webserver encompass the
metric clashscore (number of serious clashes per 1,000 atoms),
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FIGURE 4 | Molecular interactions of LabMol-171 with (A) CDPK1(cyan), (B) CDPK4 (purple), and (C) PK6 (orange) obtained by docking. In 3D representation (left),
hydrogen bonds are presented as yellow dashed lines, and the color code of oxygen, nitrogen and hydrogen atoms are red, blue, and white, respectively. The carbon
atoms of LabMol-171 colored as gray. In 2D interaction diagrams (right) hydrogen bond are presented as magenta arrows.
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which analyses steric overlap ≥0.4Å between non-bonded
atoms that bring energy penalty; poor/favored rotamers, which
evaluate the sidechain geometry conformation; outlier/favored
Ramachandran, which evaluate protein backbone conformation
by phi and psi backbone dihedrals; Molprobity score, which
is represented by a number resulting from the combination
of the clashscore, percentage of Ramanchandran not favored
and percentage of bad side-chain rotamers, which reflects
on a crystallographic resolution value; among others (Chen
et al., 2010). After our investigation, we could conclude that
clashscore andMolprobity score were within the desirable values,
and 96.70–99.30% of the rotamers were in a favored state.
Analyzes made for the values of Ramachandran pointed out
that 97.25–98.30% of residues are within the favored region
against 0.21–0.34% are classified as outliers. Thus, the overall
stereochemistry and atoms conformation analysis displayed
good quality of modeled kinases, approving them to use in
docking studies.
The most promising compound, LabMol-171 (EC50 =
0.35µM against 3D7 and SI = 138.26 on COS7 cell) was docked
into the three protein kinases (PfCDPK1, PfCDPK4, and PfPK6)
to shed some light into the interaction pattern between the ligand
and the proteins. A MM-GBSA calculation was performed in
order to calculate the free energy of binding. Figure 4 displays
the interaction between the protein kinases and LabMol-171, the
most promising experimental hit, Glide score and MMGBSA-
1G values.
As we can see on Figure 4, the best free energy between
LabMol-171 and protein kinases was obtained for calcium-
dependent kinases. LabMol-171 could interact with CDPK4
(MM-GBSA-1G = −51.93 Kcal/mol) by hydrogen bonds
at hinge region (Asp148, Tyr150) and the catalytic loop
(Lys195). In relation to CDPK1 (MM-GBSA-1G = −47.32
Kcal/mol), hydrogen bonds were established with Lys85
and with residues belonging to the hinge region (Glu146,
Tyr148), DFG motif (Asp212), catalytic loop (Asn196),
and G-loop (Ala66). Aher and Roy (Aher and Roy, 2017)
have showed the importance of some residues of CDPK1,
including Val211, Tyr148, and Phe147 for PfCDPK1
inhibitory activity.
For the docking results with PK6, a Cyclin-Dependent Kinase,
LabMol-171 presented a lower Glide score (−4.45 Kcal/mol),
showing high affinity with good values for free energy of binding
(MM-GBSA-1G=−45.08 Kcal/mol). This kinase interacts with
ligand in the hinge (Cys102) and catalytic loop regions (Glu147).
Besides that, LabMol-171 was able to interact with Asp 105 and
Asn108 of PK6.
Through our docking analysis, we could indicate that
LabMol-171 could be a potential multi-kinase inhibitor, being
able to interact mainly with hinge and catalytic loop region
of these protein kinases. Besides that, previous studies have
showed quinazoline scaffold inhibiting other molecular targets,
as dihydrofolate reductase (Patel et al., 2019a,b) and prolyl-tRNA
synthetase (Jain et al., 2017), besides kinases. So, prospective
experimental target-fishing assays must be performed to
understand the mechanism of action of quinazoline compounds
in Plasmodium.
CONCLUSION
In this work, we developed robust and predictive shape-
based and machine learning models, able to prioritize 10
promising hits as antimalarial candidates. Three compounds,
LabMol-171, LabMol-172 and LabMol-181, reached activity
in nanomolar concentration against P. falciparum strains,
besides low cytotoxicity on mammalian cells. Moreover,
these compounds did not show cross resistance with multi-
drug resistant strain, suggesting a different mechanism of
action. Besides that, LabMol-171 and LabMol-181 also showed
considerable inhibition of ookinete formation in P. berghei
standing out as powerful transmission blockers. Furthermore,
a docking study shed some light into LabMol-171 interactions
with CDPK1, CDPK4, and PK6 and suggests that this
could be a potential MKI, being able to bind with hinge
and catalytic loop regions of proposed kinases. In future
studies, we aim to perform enzymatic assays against CDPK1,
CDPK4 and PK6, and hit-to-lead optimization studies in
order to reach new MKI antimalarial drugs, with transmission
blocking activity.
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